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Improvement of bone disease by imiglucerase
(Cerezyme) therapy in patients with skeletal
manifestations of type 1 Gaucher disease:
results of a 48-month longitudinal
cohort study
Sims KB, Pastores GM, Weinreb NJ, Barranger J, Rosenbloom BE,
Packman S, Kaplan P, Mankin H, Xavier R, Angell J, Fitzpatrick MA,
Rosenthal D. Improvement of bone disease by imiglucerase (Cerezyme)
therapy in patients with skeletal manifestations of type 1 Gaucher
disease: results of a 48-month longitudinal cohort study.
Clin Genet 2008: 73: 430–440. # Blackwell Munksgaard, 2008
Progressive skeletal disease accounts for some of the most debilitating
complications of type 1 Gaucher disease. In this 48-month, prospective,
non-randomized, open-label study of the effect of enzyme replacement
therapy on bone response, 33 imiglucerase-naı¨ve patients (median age
43 years with one or more skeletal manifestations such as osteopenia,
history of bone crisis, or other documented bone pathology) received
imiglucerase 60 U/kg/2 weeks. Substantial improvements were observed
in bone pain (BP), bone crises (BC), and bone mineral density (BMD).
Improvements in BP were observed at 3 months (p , 0.001 vs baseline)
and continued progressively throughout the study, with 39% of patients
reporting pain at 48 months vs 73% at baseline. Eleven of the 13 patients
with a pre-treatment history of BC had no recurrences. Biochemical
markers for bone formation increased; markers for bone resorption
decreased. Steady improvement of spine and femoral neck BMD,
measured using dual-energy X-ray absorptiometry was noted. Mean Z
score for spine increased from 20.72   1.302 at baseline to near-normal
levels (20.09   1.503) by month 48 (p ¼ 0.042) and for femoral neck
from 20.59   1.352 to 20.17   1.206 (p ¼ 0.035) at month 36. This
increase was sustained at 48 months. With imiglucerase treatment,
patients should anticipate resolution of BC, rapid improvement in BP,
increases in BMD, and decreased skeletal complications.
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430Gaucher disease (GD) is an autosomal recessive
lysosomal storage disease resulting from deficiency
of lysosomal glucosylceramide b-glucosidase.
Consequently, lysosomes of the reticuloendo-
thelial system accumulate glycolipids, creating
engorged macrophages (Gaucher cells), which
displace normal tissue and result in dysfunction
in many organs. Clinical manifestations of the
disease include anemia, thrombocytopenia,
hepatosplenomegaly, and skeletal complications
including bone pain (BP) and bone crisis, cortical
and medullary infarctions, cortical bone thin-
ning, medullary expansion, osteopenia, osteoly-
sis, osteonecrosis, and pathological fractures (1).
Investigative trials and extended clinical use of
recombinant b-glucocerebrosidase (imiglucerase,
Cerezyme
) in more than 3000 patients have
shown improvement in GD manifestations such
as anemia, thrombocytopenia, hepatosplenome-
galy, and physical debility (2–4).
Skeletal involvement is the most frequent
debilitating complication of GD and generally
has a greater impact on quality of life (QOL)
than the hematologic and visceral abnormalities
(4–6). Skeletal disease is variable but nonetheless
progressive in its course and does not resolve
spontaneously. The pathophysiologic basis of
the skeletal complications of type 1 GD is
incompletely understood. Altered bone forma-
tion (remodeling defects and Erlenmeyer flask
deformity), altered bone resorption (osteolysis,
osteopenia, and osteoporosis) and focal bone
lesions (cortical and medullary infarctions and
pathological fractures) may be observed (1). It is
likely that complex mechanisms account for the
heterogeneity of Gaucher bone disease (7–9).
Recent observations have emphasized the signif-
icance of decreased bone density in the pathobio-
logy of GD (10). In analysis of data from the
International Collaborative Gaucher Group
(ICGG) Gaucher Registry, osteopenia or osteo-
porosis, usually detected by dual-energy X-ray
absorptiometry (DXA), was reported in 300/706
patients (42%) (11). Depending on the extent of
loss of bone mass, osteopenia and osteoporosis in
the general population are associated with an
age-related 10-year fracture risk of 8% to 45%
(12). Some studies have suggested that osteopenia
in GD may be treatable with imiglucerase. Im-
provements in bone mass were noted in pediatric
patients treated with imiglucerase for over
3.5 years (13). A retrospective analysis in adults
using linear mixed model analysis demonstrated
that bone mineral density (BMD) as measured by
DXA improved with enzyme replacement therapy
(ERT) in a dose–responsive manner over time
(10). Furthermore, alendronate was synergistic
with ERT in improving bone density and clinical
outcomes (14). In retrospective studies, imiglucer-
ase treatment markedly decreased the occurrence
of bone crises (BC) and ameliorated BP (4, 15).
This study provides the first prospective, long-
term analysis that extends to 4 years of treat-
ment of the effects of ERT on DXA-measured
BMD in a single cohort of primarily adult GD
patients and is complementary to other studies.
In previously reported analyses from the current
prospective clinical trial, we have shown that
imiglucerase improves health-related QOL in
patients with skeletal manifestations of GD (16).
Here, we confirm that imiglucerase improves the
clinical consequences of bone manifestations in
GD including BP, BC, and BMD measurements.
Methods
This was a multicenter, open-label, single-
cohort, prospective study using within-patient
comparisons to baseline to evaluate the effective-
ness of imiglucerase in treating skeletal manifes-
tations of type 1 GD in patients who had not
previously received enzyme therapy. All patients
signed an informed consent form, approved by
institutional review boards, prior to enrollment
in the study. The study was performed in compli-
ance with Good Clinical Practice and the Decla-
ration of Helsinki.
Inclusion requirements included confirmed type
1 GD, age 10–70 years, and at least one of the
following: history of at least one bone crisis, os-
teoarticular necrosis, medullary infarction, lytic
lesions, pathological fractures or fractures related
to GD, marrow infiltration with a unilateral
Rosenthal magnetic resonance imaging (MRI)
score  3 (7), bone density by DXA or quantita-
tive computerized tomography scan Z score
 21.5, or Erlenmeyer flask deformity. The inclu-
sion criteria were amended 12 months into the
study to require DXA femoral neck T score
 21.0. The exclusion criteria included peri-
menopausal status, major concurrent disorders,
non-ambulatory status, more than one joint re-
placement, prior enzyme therapy (enrollment was
permitted up to 12 weeks after first infusion of
enzyme), gene therapy, bone marrow transplanta-
tion, and use of medications known to affect
bone homeostasis, including bisphosphonates.
Patients were treated on study from September
1997 to June 2004. Patients received 60 U/kg/
2 weeks of commercial imiglucerase by intrave-
nous infusion for the first 24 months of therapy.
After 24 months, the dose could be reduced to
45 or 30 U/kg/2 weeks if a central review com-
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431mittee determined that the patient had adequate
hematological and visceral function and im-
provement in skeletal manifestations. Treatment
duration was up to 48 months.
Medical history and physical examination, as-
sessments of physician-reported BP and BC,
complete blood counts with differential, and
recording of concomitant medications, proce-
dures, and illnesses were performed on entry and
thereafter every 3 months. BP was assessed by
patient report on a six-point scale: none, very
mild, mild, moderate, severe, or extreme. Bone
crisis was defined as pain with acute onset
requiring immobilization of the affected area,
narcotics for pain relief and may be accompa-
nied by one or more of the following: periosteal
elevation, elevated white blood cells, fever, or
debilitation of .3 days.
Serum chemistries, angiotensin-converting
enzyme, and serum and urine biochemical markers
of bone metabolism (osteocalcin, bone-specific
alkaline phosphatase, type 1 collagen crosslinked
N-telopeptide, and deoxypyridinoline crosslinks)
were assessed every 6 months. Bone biochemical
marker assays were performed in the laboratory
of Thomas Clemens at the University of Cincin-
nati College of Medicine. Liver and spleen vol-
umes were measured every 12 months using MRI.
To ensure consistency of results, DXA scans
of the lumbar spine, femur, and forearm were
performed for all patients at the same site
(Massachusetts General Hospital) with a Hologic
4500QDR. The calibration of the scanners as well
as reporting of spinal density T scores and Z
scores were performed according to manufac-
turers’ recommendations following standard clini-
cal procedures. Similar procedures were followed
for the femur, greater trochanter, and the forearm
(1/3 radius 1 ulna). We chose to focus primarily
o nZs c o r e si np r e s e n t i n gB M Dc h a n g e sf o rt h i s
study population given that the patients were not
a homogeneous group in terms of age and gender.
Evaluation of treatment-induced changes in T
scores over a period of years might be confounded
by expected age-related changes during that
period. Additional skeletal evaluations included
single-energy quantitative computerized tomogra-
phy, MRI quantitative chemical shift imaging,
X-ray assessments, and coronal MRI. These
modalities were used to evaluate skeletal manifes-
tations as reported in Table 3. Detailed results
from these analyses will be reported separately.
All statistical comparisons were carried out as
2-sided tests. Analyses were conducted for the
intent-to-treat (ITT) population, which included
all patients enrolled in the study.
Results
Baseline characteristics
Thirty-three patients were treated (Table 1). All
but one patient had at least one N370S allele;
67% were N370S homozygous. A total of 23
patients (70%) were of Ashkenazic Jewish ethnic-
ity. Only one patient was less than 22 years of age.
Signs of significant pre-treatment, non-skeletal
systemic disease in these patients, including spleno-
megaly and hepatomegaly, are listed in Table 2.
Five patients (15%) had undergone total splenec-
tomy. At baseline, 9 patients (27%) reported no
skeletal pain and 24 patients (73%) reported pain
– 12 patients (36%) very mild or mild pain, 8
(24%) moderate pain, and 4 (12%) severe or
extreme pain (Fig. 1, top). Twelve patients (36%)
Table 1. Patient disposition and demographics
Parameter Measure
Number of patients treated 33
Number of patients not
completing study, n (%)
10 (30)
Principal reason for withdrawal, n (%)
Adverse events 1 (3)
Uncooperative (could not make visits) 1 (3)
Wishes to withdraw 3 (9)
Sponsor ended study 3 (9)
Others (lung cancer and
circumstances prevented
further participation)
2 (6)
Study treatment duration, months,
median (range)
49.4 (4.2–58.6)
Time of last efficacy visit, n (%)
 12 months 6 (18)
.12 to  24 months 0
.24 to  36 months 4 (12)
.36 to 48 months 23 (70)
Gender, n (%)
Male 19 (58)
Female 14 (42)
Ethnicity, n (%)
Ashkenazi Jewish 23 (70)
Non-Jewish Caucasian 6 (18)
African-American/Caribbean 1 (3)
Hispanic 2 (6)
American Indian 1 (3)
Others 2 (6)
Genotype, n (%)
N370S N370S 22 (67)
N370S-L444P 6 (18)
N370S-D409H 1 (3)
N370S-IVS211 1 (3)
N370S-unknown 2 (6)
Unknown 1 (3)
Patients with total
splenectomy, n (%)
5 (15)
Median age at Gaucher symptom
onset, years (range)
32.0 (11.0–52.0)
Median age at consent, years (range) 43.0 (12.0–70.0)
Median weight at baseline, kg (range) 64.2 (34.0–105.0)
Median height at baseline, cm (range) 169.9 (146.5–190.5)
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432had evidence of prior medullary infarction, 12
(36%) had lytic lesions, 2 (6%) had osteoarticular
necrosis, 1 (3%) had long bone fracture, and 1
(3%) had spine fracture (Table 3). For the lumbar
spine, 18/31 patients with baseline data (58%) were
osteopenic at baseline by DXA T score (T score
 21.0) and 6 patients (19%) had osteoporosis
(T score  22.5). For the femoral neck, 26/32 pa-
tients (81%) were osteopenic at baseline. None of
the enrollees had a history of joint replacement.
Study compliance and dosing
Of 33 treated patients, 27 patients (82%) had effi-
cacy evaluations at 24 months; 23 patients (70%)
completed the 48-month study and 10 patients did
not complete the study (Table 1). Most patients
received an imiglucerase dose of 60 U/kg/2 weeks
for the entire study. Nine patients had dose reduc-
tions from 60 to 45 or 30 U/kg generally after the
month 24 visit (one patient had dose reduction to
45 U/kg at month 18). The median dose at all
time points was 60 U/kg/2 weeks, except for
month 45 where it was 56.1 U/kg/2 weeks. Missed
infusions were uncommon. Twenty-three patients
(70%) missed no infusions, and only two patients
missed five or more infusions.
Bone pain
Reduction in patient-reported pain levels was
evident by month 3 (Fig. 1, top). By month 6,
the number of patients with any reported BP
had fallen from 24/33 (73%) to 15/31 (48%). In
months 18 through 48, the percentage of patients
with any pain plateaued at approximately 40%.
Twelve of 33 patients (36%) reported moderate,
severe, or extreme pain at baseline; only 6/32 pa-
tients (19%) reported these pain levels at month
3, and less than 20% of patients reported these
levels at any time point from month 24 onward.
At month 48 (n ¼ 23 completing patients), 14
patients (61%) had no pain, 6 patients (26%)
had very mild or mild pain, 3 patients (13%) had
moderate pain, and no patient had severe or
extreme pain. These changes were not because
of withdrawal of patients with pain from the
study – of the 10 patients who discontinued, only
3 had any pain at their last evaluation (1 very
mild, 1 mild, and 1 severe). Pain reported by the
23 patients who completed the study was similar
to reports given by the total population of 33
patients (data not shown).
Patient reports of BP over time were compared
with their reported pain at baseline for improve-
ment, worsening, or no change (Fig. 2, bottom).
Patients with pain improvement over baseline
were noted at all time points. In addition, the
percentage of patients with worsening BP com-
pared with baseline decreased over time to
 10% by month 24. These improvements were
statistically significant (p , 0.001 at all time
points). Of the nine patients with no pain at
baseline, only three reported BP at any time
during the course of the study.
Bone crisis and skeletal complications
The number of patients reporting BC decreased in
the first 12 months and remained below baseline
for the remainder of the study (Table 3). At study
entry, 13/33 patients (39%) had a history of BC,
with 5 of these patients (15%) reporting BC in the
2 months immediately preceding initiation of imi-
glucerase. In the first year of the study, only two
patients reported new BC (n ¼ 32 at month 12).
After month 12, only one patient reported a bone
crisis per 12-month period, and between 24 and
36 months, no crises were reported (n ¼ 29, 27,
and 23 patients with evaluations at months 24, 36,
and 48, respectively). Overall, three patients re-
ported BC post-baseline; two of these patients
had prior history of bone crisis. Eleven of 13
patients with a history of BC (85%) did not have
a crisis during the 48-month study.
Most incidents of medullary infarctions, osteo-
articular necrosis, the appearance of lytic lesions,
and/or long bone and spinal fractures occurred
within the first 24 months of the study; only two
events, both spinal fractures, were noted past
month 24 of the study (Table 3). Events during
the study were much more likely to occur in
patients with pre-existent skeletal complications.
All post-treatment complications were identified
in the course of radiological monitoring and
were not associated with clinical symptoms.
DXA bone density measurements
Mean lumbar and femoral neck DXA Z scores
(Fig. 2) and T scores (data not shown) improved
Table 2. Non-skeletal measures of disease
Measure Baseline result Month 48 result
a
Platelet count,
310
9/l, mean (SD)
n ¼ 33, 120 (60.7) n ¼ 23, 198 (59.6)
Hemoglobin,
g/dl, mean (SD)
n ¼ 33, 12.9 (1.48) n ¼ 23, 14.5 (1.72)
Liver size, 3normal,
mean (SD)
n ¼ 29, 1.4 (0.52) n ¼ 22, 1.0 (0.24)
Spleen size, 3normal,
mean (SD)
n ¼ 26, 6.5 (3.34) n ¼ 19, 3.6 (1.74)
ap Value ,0.001 testing the hypothesis that the mean
percent change is equal to zero using a t-test.
Imiglucerase in Gaucher bone disease
433progressively with imiglucerase treatment. In the
lumbar vertebrae, the mean baseline Z score  
SD was 20.72   1.302, which corresponds to
a mean density of 0.926   0.142 g/cm
2 and a
mean T score of 21.27   1.257. A trend toward
improvement in DXA Z score of the lumbar
vertebrae L1 to L4 over baseline was apparent
by month 12, while statistically significant
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Note:  Statistically significant improvement
vs baseline at all time points (p < 0.001)
Fig. 1. Bone pain (BP) over time. Top – self-reported pain levels over time. Patients were asked to report their BP levels as
none, very mild, mild, moderate, severe, or extreme every 3 months. The percentage of patients with any pain (top line) or
moderate, severe, or extreme pain (bottom line) was determined and graphed over time. At baseline, 9 patients (27%) reported
no pain, 12 (36%) very mild or mild pain, 8 (24%) moderate pain, and 4 (12%) severe or extreme pain. Bottom – changes in
patient-reported pain. The percentage of patients with improved, stable, or worsened pain compared with the pain level
reported at baseline is shown.
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434improvement was observed starting at month 24
and continuing through month 48 (p , 0.05). By
month 48, the mean Z score had reached near-
normal levels (20.09   1.503, corresponding to
a mean density of 1.003   0.183 g/cm
2 and
a mean T score of 20.67   1.587). Improvements
Table 3. Skeletal events
Skeletal manifestation
Patients with
evidence, n (%)
Occurrence of post-baseline
events (month)
At baseline or by history Post-baseline 0–12 .12–24 .24–36 .36–48
Medullary infarction 12 (36) 4 (12) 2 2 0 0
Osteoarticular necrosis 2 (6) 5 (15) 4 1 0 0
Lytic lesions 12 (36) 3 (9) 1 2 0 0
Fractures
Long bone 1 (3) 0 0 0 0 0
Spinal 1 (3) 3 (9) 0 1 1 1
Bone crisis 13 (39)
a 3 (9) 2 1 0 1
aThirteen patients had a history of bone crisis at any time prior to baseline; at baseline, five of these patients reported having
a bone crisis in the past 2 months.
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Fig. 2. Bone density (mean dual-energy X-ray absorptiometry Z scores, reflective of age-adjusted normal) as measured in the
spine (a), femoral neck (b), greater trochanter (c), and 1/3 radius 1 ulna (d). P values test the hypothesis that the mean change
is equal to zero (t-test). *p , 0.05.
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435were also seen in the femoral neck. Mean Z scores
increased from 20.59   1.352 at baseline (corre-
sponding to a mean bone density of 0.769  
0.162 g/cm
2 and a mean T score of 21.53  
1.274) to 20.17   1.206 at month 36 (p ¼ 0.035,
corresponding to a mean bone density of 0.791  
0.175 g/cm
2 and a mean T score of 20.88  
1.244). This level of change was sustained at
48 months, but because of the loss of two pa-
tients, statistical significance was lost (p ¼ 0.231).
However, significant changes did not occur either
at the greater trochanter or in the distal third of
the radius and ulna.
A summary of DXA results and skeletal events
for individual patients is shown in Table 4. Im-
provements in BMD were not dependent on
splenectomy status, age, baseline BMD, or
occurrence of spinal fractures during the study
(data not shown).
An additional analysis was performed exclud-
ing patients from the ITT population for factors
that might have affected the analysis of BMD
[patients 5603, 6204, 6303, and 6307 were miss-
ing baseline or follow-up data; patient 5606 was
excluded from the lumbar vertebrae analysis
because of a compression fracture; patient 5607
was the only non-adult (12 years old); patients
5701 and 5704 were excluded for bisphosphonate
use and patients 6201 and 6203 for hormone
replacement therapy use]. In this analysis,
changes in the lumbar vertebrae were statisti-
cally significant at months 24 (p ¼ 0.046) and 36
(p ¼ 0.011), although the magnitude of changes
were smaller than in the overall population
(mean Z scores increased from 20.54   1.346
at baseline to 20.25   1.151 at month 48,
corresponding to a mean bone density of
0.0954   0.130 g/cm
2 and a mean T score of
Table 4. Summary of patient results
Patient
Sex, age
at consent
(years) Splenectomy? Genotype
Baseline
spine DXA
Z score
End of study
spine DXA
Z score
Baseline
femur DXA
Z score
End of study
femur DXA
Z score
Last DXA
time point
(months)
Skeletal events
a
Baseline After
5001 F, 40 N N370S/N370S 20.09 20.10 21.62 21.10 12 L
5002 F, 51 Y ?/? 20.42 20.40 20.96 20.50 48 B B
5601 M, 32 N N370S/N370S 21.29 21.50 21.50 20.80 48
5602 M, 22 N N370S/N370S 20.60 0.00 0.72 0.90 48 L OBLM
5603 M, 53 N N370S/N370S 3.30
b 2.40 1.43 1.20 48
5604 M, 59 N N370S/N370S 21.81 20.90 21.75 21.40 48 OB S
5605 M, 36 N N370S/N370S 20.66 0.00 20.76 0.00 48
5606 M, 22 N N370S/ISV211 0.31 3.90 0.61 20.30 48 BLM OLMS
5607 F, 12 N N370S/N370S 21.00 20.20 48 BLM
5608 M, 37 Y N370S/N370S 20.36 0.30 20.88 20.10 48
5609 M, 42 N N370S/N370S 23.20 23.30 21.30 21.20 24 BLM OM
5701
c,d F, 51 N N370S/N370S 22.06 21.30 22.19 21.40 48 LM
5702 M, 38 N N370S/L444P 21.47 20.80 0.31 0.60 48 LM
5703 F, 28 N N370S/D409H 20.90 20.50 21.80 21.70 48
5704
c M, 55 N N370S/N370S 22.50 21.20 20.80 20.30 36 LM L
5801 F, 40 N N370S/? 20.35 0.05 21.10 21.22 12 BLM BO
6001 M, 68 N N370S/? 1.30 1.90 3.80 2.90 48 OBLM LM
6002 M, 64 N N370S/N370S 20.04 0.00 0.02 20.20 36
6201
d F, 44 Y N370S/L444P 22.05 22.20 21.75 21.70 48 B
6202 F, 54 N N370S/N370S 0.76 0.90 20.49 0.00 48 B
6203
d F, 70 N N370S/N370S 20.58 20.30 20.68 20.40 48 L
6204 M, 38 N N370S/N370S 21.45 22.39 BL B
6205 F, 48 N N370S/N370S 20.16 20.40 20.54 20.50 48 M S
6206 F, 39 Y N370S/L444P 22.40 21.80 21.70 21.50 36
6301 M, 41 N N370S/N370S 21.39 20.60 20.79 20.20 48
6302 M, 44 N N370S/N370S 21.70 21.60 21.07 20.50 48
6303 F, 56 N N370S/N370S 20.64 21.66 BL LS
6304 M, 64 Y N370S/N370S 3.38 2.60 0.54 0.50 48
6305 M, 54 N N370S/L444P 20.45 21.40 20.88 21.80 48 O
6306
d F, 61 N N370S/L444P 1.52 1.52 20.62 20.47 12 BLM
6307
e M, 34 N N370S/N370S
6308 F, 38 N N370S/L444P 20.96 20.80 21.03 21.00 48 BM
6309 M, 43 N N370S/N370S 21.13 21.10 2.57 2.20 48 BML
DXA, dual-energy X-ray absorptiometry; ?/?, unknown/unknown allele mutations.
aB, bone crisis; L, lytic lesion; M, medullary infarction; O, osteoarticular necrosis; S, spinal fracture.
bNo baseline data available. 3.30 is at 24 months.
cPatient received bisphosphonates (protocol deviation). Patient 5701 received pamidronate from month 21 and patient 5704
received fosamax from month 18.
dPatient received hormone replacement therapy.
ePatient 6307 discontinued from the study after one infusion and no baseline scans because of inability to comply with visit
schedule.
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43621.00   1.160 at baseline vs a mean bone den-
sity of 1.000   0.116 g/cm
2 and a mean T score
of 20.75   1.019 at month 48). Statistically sig-
nificant changes in the femoral neck Z score
were observed at month 36 (p ¼ 0.044), and the
magnitude of changes were similar to the overall
population (mean Z scores increased from
20.48   1.342 at baseline to 20.09   1.216 at
month 48, corresponding to a mean bone density
of 0.788   0.166 g/cm
2 and a mean T score of
21.36   1.280 at baseline vs a mean bone den-
sity of 0.813   0.166 g/cm
2 and a mean T score
of 20.79   1.192 at month 48).
Markers of bone metabolism
Although median baseline measurements of
osteocalcin, bone-specific alkaline phosphatase,
N-telopeptide crosslinks, and deoxypyridinoline
(D-PYD) at baseline fell within the normal
range, median post-treatment measurements for
bone formation markers, osteocalcin and bone-
specific alkaline phosphatase increased by
approximately 60% in the first 12 months of the
study and consistently remained above baseline
values throughout the study (Fig. 3, top). These
results reflected statistically significant changes
from baseline at all time points. At month 12,
25 patients (93%) had an increase in osteocalcin
over baseline and 24 patients (89%) had an
increase in alkaline phosphatase over baseline;
at all time points, at least 74% of patients
showed increases in these markers over baseline,
although some increases were small. Between 36
and 48 months, median levels of bone resorption
markers, N-telopeptide crosslinks and D-PYD
decreased approximately 20–40%, although
these changes were generally not statistically
significant (Fig. 3, bottom). For each of these
measures, at month 36, 15 patients (68%) had
a decrease from baseline. These results suggest
a shift favoring new bone formation relative to
bone resorption and are consistent with the
observed progressive increase in vertebral and
femoral neck BMD.
Hematologic and visceral responses and safety
Improvements in platelet count, hemoglobin,
and spleen and liver volumes were consistent
with other studies of imiglucerase in patients
with GD (4) (Table 2). The safety results from
this study were consistent with the results ex-
pected based on the package labeling and results
from previous studies (4). Overall, the most com-
mon adverse events were chills (seven events),
flushing (six events), and arthralgia (six events),
each reported in four patients (12%). One
patient withdrew from the study and treatment
because of a severe infusion reaction, including
anxiety, chest pain, hypertonia, chills, tachycar-
dia, and vomiting, from which he recovered
without sequelae.
Discussion
Our study results show a decrease in BP and
skeletal complications and an increase in BMD
in patients with type 1 GD treated with imiglu-
cerase. Despite the predominance of the N370S
genotype in these patients and the relatively mild
hematological and visceral disease in this cohort,
the patients had evidence of serious skeletal dis-
ease at baseline. When this study was initiated,
imiglucerase was the sole proven effective ther-
apy available for the hematological and visceral
manifestations of type 1 GD found in our pa-
tients. Therefore, there was neither any alternative
treatment arm proposed nor was a placebo arm
included. There is, in fact, no evidence suggesting
that established untreated Gaucher bone disease
is spontaneously reversible (1). Untreated, BP and
bone crisis are frequently associated with irre-
versible bone pathology that leads to morbidity,
deformity, fractures, multiple orthopedic surger-
ies, decreased QOL, and early mortality.
Decreased BMD is commonly observed in
both men and women with type 1 GD (17). Sev-
eral studies have assessed the effect of ERT on
BMD in GD, with variable results. Rosenthal
et al. observed significant increases in cortical
thickness after 42 months of treatment (13).
Using DXA, Ciana et al. reported statistically
significant improvements in BMD at a mean
follow-up time of 4.5 years (18). However,
Schiffmann et al. found a decrease in BMD using
QCT of the lumbar spine in patients receiving
ERT (19) and Lebel et al. reported a mixture
of improvement, no change, or decline over
a period ranging from 24 to 108 months using
DXA (20). These results are difficult to compare
and interpret because the studies were performed
in different patient populations (pediatric vs adult
patients and different doses of ERT) and different
methodologies were used to assess BMD.
DXA measurements are quantitative, repro-
ducible, widely available in developed countries,
and relatively inexpensive. The progressive in-
crease in lumbar spine and femoral neck BMD
that we observed supports previous suggestions
that serial DXA measurements of these sites be
Imiglucerase in Gaucher bone disease
437included when monitoring the response to treat-
ment in patients with type 1 GD (4) and that
improving lumbar and femoral BMD is an
appropriate therapeutic goal (21). The increases
in BMD noted in this paper, which appeared
more quickly than noted in some other studies
using various doses of imiglucerase in GD (18,
20), suggest that the dosage used in this study
(60 U/kg/2 weeks) may be an appropriate start-
ing dose in osteopenic patients. Additionally, the
lack of change in forearm BMD measurements
indicates that assessment of this site may not pro-
vide clinically meaningful information when used
in the monitoring of patients with type 1 GD.
Our results are consistent with, and comple-
mentary to, the recently published retrospective
analysis from the ICGG Gaucher Registry. This
analysis, in 342 ERT-treated patients, showed
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438that pre-treatment lumbar DXA Z scores were
significantly below normal but progressively
improved with treatment over an 8-year period
with a significant dose–response relationship
(10). In our study, patients received imiglucerase
60 U/kg every 2 weeks. This dose was noted to
be the most effective in the Gaucher Registry
study. Unlike the Gaucher Registry analysis,
however, our trial is not confounded by possible
concurrent use of bisphosphonates or by vari-
ance in DXA machine type or protocol,
although other potential confounders such as
smoking and use of female hormone replacement
started prior to ERT are not excluded. In our
patient cohort, improved BMD occurred concur-
rently with decreases in BC and BP. Of note, the
incidence of fractures was low throughout the
48 months of the study. Few events occurred
after month 24, and it is possible that events
occurring early in the study were because of dis-
eases present at baseline. Our study, however,
neither demonstrated a definitive correlation
between BMD and skeletal complications nor do
we have any evidence as yet that increasing
BMD in patients with type 1 GD will result in
long-term reduction in fracture risk as has been
shown in women with post-menopausal osteopo-
rosis (22). Nevertheless, improving BMD appears
to be of benefit in other chronic inflammatory
diseases with associated osteopenia such as rheu-
matoid arthritis and Crohn’s disease (23, 24), and
it is likely that further cumulative experience with
ERT in GD will show similar results. The treat-
ment-associated decreases in BP, and in occur-
rence of BC observed in this prospective study,
are consistent with the retrospective experience
reporting improvement in BP and BC in larger
number of patients from the International
Gaucher Registry (15).
Although some previous studies have found
that classical biochemical markers for bone for-
mation (osteocalcin and bone-specific alkaline
phosphatase) are of limited clinical value for
monitoring the response to ERT in patients with
type 1 GD (18), our results, which demonstrate
a consistent increase in these markers, suggest
that further investigation of the utility of these
markers to monitor bone formation is warranted.
Increases in bone formation markers from base-
line values have been used as an index of response
in patients treated for post-menopausal osteo-
penia (25). Adjuvant treatment of osteopenia/
osteoporosis in patients with type 1 GD has
largely focused on inhibition of osteoclasts and
retardation of bone resorption with bisphospho-
nates (14). However, the lack of consistent changes
in markers of bone resorption (N-telopeptide
crosslinks and D-PYD) suggests that they may
be of limited utility in monitoring bone re-
sponse to ERT in GD. Our preliminary findings
revealed that imiglucerase may enhance bone
formation in osteopenic GD patients and con-
firm the results of Schiffmann et al. (19). Pro-
spective trials using anabolic bone agents may
be worthwhile to undertake in imiglucerase-
treated GD patients with persistent osteopenia
to determine whether bone formation and
BMD can be further enhanced.
In summary, this prospective study confirms
that ERT with imiglucerase improves the major
symptomatic manifestations of Gaucher skeletal
disease, bone crisis and BP, decreases the risk of
skeletal events (infarction, lytic lesions, and frac-
ture), and increases lumbar spine and femoral
neck BMD during the first 4 years of treatment.
Our results suggest that early initiation of treat-
ment in symptomatic patients can substantially
alleviate discomfort and may prevent poten-
tially disabling bone complications and overall
morbidity.
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